PURPOSE: Many trials do not measure quality-adjusted life years (QALYs). Therefore, decision analysts often map condition-specific outcomes to preference scores. We estimated the relationship between changes in preference scores and commonly reported condition-specific outcomes in patients with urinary incontinence (UI) due to neurogenic detrusor overactivity. METHODS: In 59 patients recruited to a neurogenic UI trial, clinical outcomes (UI episodes), condition-specific quality of life (Incontinence Quality of Life Instrument (I-QOL)), and SF-6D preference scores were measured at enrollment and 24 weeks. We used multiple linear regression to estimate the impact on SF-6D scores of 50; 50-99 and 100% reductions in UI episodes and a 10-point improvement in I-QOL. RESULTS: By 24 weeks, mean (95% CI) daily UI episodes fell by 0.85 (0.04, 1.3) and mean I-QOL scores improved by 18 (12, 24). SF-6D scores increased by 0.03 (0.003, 0.058), due to improvements in role limitations. A > or = 50% reduction in UI episodes was achieved by 49% of patients and corresponded to a 0.09 (0.02, 0.16) SF-6D increase. A > or = 10-point increase in I-QOL was attained by 65% of patients and was associated with a 0.05 (-0.02, 0.12) SF-6D increase. CONCLUSIONS: These estimates provide preliminary data for decision analysts wishing to map neurogenic UI outcomes to preference scores.
RCT Entities:
PURPOSE: Many trials do not measure quality-adjusted life years (QALYs). Therefore, decision analysts often map condition-specific outcomes to preference scores. We estimated the relationship between changes in preference scores and commonly reported condition-specific outcomes in patients with urinary incontinence (UI) due to neurogenic detrusor overactivity. METHODS: In 59 patients recruited to a neurogenic UI trial, clinical outcomes (UI episodes), condition-specific quality of life (Incontinence Quality of Life Instrument (I-QOL)), and SF-6D preference scores were measured at enrollment and 24 weeks. We used multiple linear regression to estimate the impact on SF-6D scores of 50; 50-99 and 100% reductions in UI episodes and a 10-point improvement in I-QOL. RESULTS: By 24 weeks, mean (95% CI) daily UI episodes fell by 0.85 (0.04, 1.3) and mean I-QOL scores improved by 18 (12, 24). SF-6D scores increased by 0.03 (0.003, 0.058), due to improvements in role limitations. A > or = 50% reduction in UI episodes was achieved by 49% of patients and corresponded to a 0.09 (0.02, 0.16) SF-6D increase. A > or = 10-point increase in I-QOL was attained by 65% of patients and was associated with a 0.05 (-0.02, 0.12) SF-6D increase. CONCLUSIONS: These estimates provide preliminary data for decision analysts wishing to map neurogenic UI outcomes to preference scores.
Authors: R A Schmidt; U Jonas; K A Oleson; R A Janknegt; M M Hassouna; S W Siegel; P E van Kerrebroeck Journal: J Urol Date: 1999-08 Impact factor: 7.450
Authors: Karl Claxton; Mark Sculpher; Chris McCabe; Andrew Briggs; Ron Akehurst; Martin Buxton; John Brazier; Tony O'Hagan Journal: Health Econ Date: 2005-04 Impact factor: 3.046
Authors: Leslee L Subak; Jeanette S Brown; Stephen R Kraus; Linda Brubaker; Feng Lin; Holly E Richter; Catherine S Bradley; Deborah Grady Journal: Obstet Gynecol Date: 2006-04 Impact factor: 7.661
Authors: Garry R Barton; Tracey H Sach; Anthony J Avery; Claire Jenkinson; Michael Doherty; David K Whynes; Kenneth R Muir Journal: Health Econ Date: 2008-07 Impact factor: 3.046
Authors: Michael B Chancellor; Vaishali Patel; Wendy W Leng; Patrick J Shenot; Wayne Lam; Denise R Globe; Alex L Loeb; Christopher R Chapple Journal: Neurology Date: 2013-07-26 Impact factor: 9.910
Authors: Crisanta I Tapia; Kristin Khalaf; Karina Berenson; Denise Globe; Michael Chancellor; Lesley K Carr Journal: Health Qual Life Outcomes Date: 2013-01-31 Impact factor: 3.186